CDK 4/6 inhibitors combined with radiotherapy: A review of literature

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) namely palbociclib, ribociclib and abemaciclib were granted approval by the European Medicines Agency (EMA) between 2017 and 2018. They are currently prescribed in combination with hormone therapy to treat hormone receptor positive, HER2 negative...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Transl Radiat Oncol
Asıl Yazarlar: Bosacki, Claire, Bouleftour, Wafa, Sotton, Sandrine, Vallard, Alexis, Daguenet, Elisabeth, Ouaz, Hamza, Cojoracu, Iohel, Moslemi, Dariush, Molekzadehmoghani, Mona, Magné, Nicolas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2020
Konular:
Review Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724290/
https://ncbi.nlm.nih.gov/pubmed/33319074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctro.2020.11.010
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller